Brett Seely
Medical · Richfield, UTNPI 1801343801
Payments from drug & device makers
Across 114 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$326
- AbbVie$308
- AstraZeneca$231
- Boehringer Ingelheim$150
- Merck$98
- Novo Nordisk$74
- plus $565 from 17 others
What the payments were for
- Food & beverage$1,753100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 23 | $326 |
| AbbVie | 23 | $308 |
| AstraZeneca | 16 | $231 |
| Boehringer Ingelheim | 6 | $150 |
| Merck | 6 | $98 |
| Novo Nordisk | 5 | $74 |
| Pfizer | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $55 |
| Eisai Inc. | 3 | $51 |
| Nestle Healthcare Nutrition Inc. | 3 | $51 |
| Johnson & Johnson | 3 | $46 |
| Organogenesis Inc. | 2 | $40 |
| Teleflex LLC | 1 | $38 |
| Corcept Therapeutics | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Organon | 3 | $27 |
| Baxter Healthcare | 1 | $23 |
| Indivior Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| GSK | 1 | $15 |
| Medtronic | 1 | $15 |
| Orthofix Medical, Inc. | 1 | $13 |
| Alkermes, Inc. | 1 | $12 |
How this compares
$1,753 in reported general payments places this provider in the 60th percentile of 263 medical providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 24 | $32,405 |
| VraylarCariprazine Hcl | 21 | $29,864 |
| TrulicityDulaglutide | 21 | $28,781 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $23,963 |
| OzempicSemaglutide | 12 | $20,198 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,537 |
| MyrbetriqMirabegron | 11 | $4,924 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 12 | $2,690 |
| Atorvastatin Calcium | 163 | $2,089 |
| Omeprazole | 126 | $1,498 |
| Potassium Chloride | 64 | $1,330 |
| Simvastatin | 60 | $1,000 |
| Celecoxib | 44 | $917 |
| Pantoprazole Sodium | 25 | $908 |
| Gabapentin | 89 | $901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $150 | $32,40524 claims |
| AbbVieVraylar | $308 | $29,86421 claims |
| Lilly USA, LLCTrulicity | $326 | $28,78121 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $17 | $23,96320 claims |
| Novo NordiskOzempic | $74 | $20,19812 claims |
| AstraZenecaSymbicort | $231 | $5,53716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 263 medical providers in Utah.
Other medical in Richfield
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$65K
- Val WarnerLayton$51K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Kelly MikesellOgden$19K
- Jennifer CoombsSlc$12K
- Brandon HansenRiverton$10K
- Daniel CorryCedar City$10K
- Mark UdySt George$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.